The estimated Net Worth of Group L.P.Crg Partners Iii ... is at least $21 Million dollars as of 26 September 2023. Group Iii owns over 5,392,920 units of T2 Biosystems Inc stock worth over $8,186,080 and over the last few years Group sold TTOO stock worth over $12,847,494.
Group has made over 7 trades of the T2 Biosystems Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Group sold 13,130,147 units of TTOO stock worth $2,232,125 on 27 September 2023.
The largest trade Group's ever made was selling 13,130,147 units of T2 Biosystems Inc stock on 27 September 2023 worth over $2,232,125. On average, Group trades about 6,043,225 units every 1 days since 2023. As of 26 September 2023 Group still owns at least 3,559,165 units of T2 Biosystems Inc stock.
You can see the complete history of Group Iii stock trades at the bottom of the page.
Over the last 10 years, insiders at T2 Biosystems Inc have traded over $18,971,153 worth of T2 Biosystems Inc stock and bought 5,875,341 units worth $59,722,018 . The most active insiders traders include Adrian M Jones, Group L.P.Crg Partners Iii ..., and Thomas J. Carella. On average, T2 Biosystems Inc executives and independent directors trade stock every 20 days with the average trade being worth of $764,499. The most recent stock trade was executed by John J Iii Sperzel on 24 February 2024, trading 67 units of TTOO stock currently worth $154.
t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www
T2 Biosystems Inc executives and other stock owners filed with the SEC include: